Prior studies investigating adjuvant cetuximab or erlotinib/gefitinib failed to improve OS in patients with LA-NSCLC and driver mutations.8–10 More recently, the phase III ADAURA trial showed the use of adjuvant osimertinib for 3 years in patients with completely resected, EGFR mutated, Stage IB-IIIA NSCLC was associated with improved DFS compared to treatment with placebo (90% vs 44%, p < 0.001). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.